# Medical Question & Answer

**Sample ID**: 18afc366-1235-4ec8-aa15-b8f879550bda
**Dataset Index**: 2528

---

## Question

I'm treating a 63-year-old female with a history of meth and hallucinogen use, diagnosed with an unspecified mood disorder, currently on Seroquel 200 mg that I will reduce to 100 mg at her request; she asked for another option for sleep, so I started mirtazapine 7.5 mg for its safety in the elderly, hoped benefit in reducing the above cravings, and sleep support. I'm considering tapering off Seroquel since it is mainly being used for sleep and she has high cholesterol and hypertension. Can you help me articulate these reasons in the treatment plan and suggest what else I can use for her depressive symptoms? Lexapro was a failed attempt.

---

## Answer

> Let's see… What do we have here? The user is asking about refining a treatment plan for a 63-year-old woman using quetiapine 200 mg nightly for sleep, newly started on mirtazapine 7.5 mg, with prior escitalopram nonresponse, focusing on whether to deprescribe quetiapine, how to taper it safely, how to justify mirtazapine, which next-line antidepressants to consider, and what monitoring and nonpharmacologic supports to include. Let's break this down step-by-step. First, I need to think about quetiapine's risk profile in older adults and whether off-label use for insomnia is justified. Then, I should verify patient-centered reasons to change therapy and the evidence base for mirtazapine, including any relevance to stimulant use disorder. Next, I will construct a cautious taper, outline antidepressant options after SSRI failure, integrate behavioral treatments, specify monitoring and documentation, and double-check for internal inconsistencies to correct them explicitly as I go, using guideline-aligned references throughout.

> Let me first confirm the risk-benefit of quetiapine in this context. Quetiapine is associated with somnolence, orthostatic hypotension, motor and sensory instability, and falls, all of which matter in older adults; it also carries warnings for metabolic changes, anticholinergic effects, and cataracts with long-term use, which are particularly relevant in a 63-year-old with hypertension and hypercholesterolemia using it solely for sleep, an off-label indication [^114YQwMB]. Wait, "contraindicates" would be too strong here; the FDA labeling highlights risks rather than absolute contraindications, so I should frame this as an unfavorable risk-benefit balance that warrants deprescribing through shared decision-making, consistent with the principle to balance effectiveness, side effects, and patient preferences [^113eCDty].

> Next, I should verify patient-centered indicators supporting change. The patient's explicit request to reduce from 200 mg to 100 mg supports shared decision-making and deprescribing momentum, and the use of antipsychotics purely for sleep in older populations is commonly flagged as inappropriate psychotropic use, prompting nonpharmacologic alternatives and safer pharmacologic substitutions when possible [^112TR8ZA]. Hold on, let me ensure I'm aligning this with best-practice principles: the WHO approach emphasizes tailoring to patient preference while balancing risks and benefits, which fits well with a planned taper and substitution strategy [^113eCDty].

> I will now justify the addition of mirtazapine. Let me think about dual aims: sleep consolidation and stimulant use history. Mirtazapine at low doses exerts sedative effects that can replace quetiapine's sedating role while avoiding antipsychotic-specific risks, and critically, contemporary ASAM/AAAP guidance suggests offering mirtazapine to promote reduced use of amphetamine-type stimulants, providing an evidence-based rationale given the patient's methamphetamine use history that quetiapine does not address [^114Gruq1]. I should confirm the broader treatment frame: combination with psychotherapy improves outcomes in depression, so using mirtazapine within a multimodal plan is consistent with guideline-based care [^112TaqDX].

> Let me consider psychosocial supports alongside pharmacotherapy for stimulant use disorder. Psychosocial treatment, including motivational interviewing and structured adherence support, improves engagement and can augment reductions in stimulant use, so integrating these modalities with mirtazapine is sensible and guideline-concordant [^113MFoy2]. I should also note that motivational interviewing and patient navigation have evidence for improving adherence in populations with mental health and substance use challenges, which fits the patient's profile and bolsters the overall plan [^117Xsqtp].

> Now, I need to ensure a safe, gradual quetiapine taper. I should double-check the label: abrupt discontinuation increases the risk of withdrawal and symptom rebound, so a stepwise taper over about eight to nine weeks is appropriate, for example 200 mg to 100 mg for weeks 1–2, then 75 mg for weeks 3–4, then 50 mg for weeks 5–6, then 25 mg for weeks 7–8, and discontinue in week 9, with pauses or slower decrements if withdrawal or rebound insomnia emerges [^111mS9W3] [^114YQwMB]. Hold on, I should verify flexibility: if insomnia flares or anxiety rises, I would maintain the current step for one to two additional weeks before proceeding, consistent with cautious deprescribing principles and patient safety priorities [^111mS9W3] [^114YQwMB].

> Next, I should review monitoring during the taper. Let me verify objective and safety metrics: track sleep quality weekly using a standardized tool such as the Pittsburgh Sleep Quality Index, monitor for withdrawal symptoms and rebound insomnia, check orthostatic vital signs because of hypotension and fall risk, and follow metabolic parameters such as lipids and fasting glucose monthly early in the taper to document improvement from stopping an agent with metabolic liabilities [^113Pode8] [^114YQwMB] [^111mS9W3]. I need to ensure cataract risk is acknowledged over the long term and that deprescribing is documented as a safety-driven intervention for this risk profile, which aligns with labeling warnings and geriatric safety priorities [^111mS9W3].

> I will now examine next-line antidepressant strategy after escitalopram nonresponse. Wait, I should confirm first-line options: WHO guidance lists sertraline among preferred agents for moderate to severe depression, and in an older adult, starting low at 25 mg daily and titrating to 50–100 mg over several weeks is a reasonable and commonly used approach consistent with these recommendations, with careful monitoring for tolerability and response [^111GYDWw]. But wait, what if SSRIs are not tolerated or ineffective again? Bupropion is a mechanistically distinct alternative that may help with energy and concentration, but I need to check blood pressure closely given the patient's hypertension; venlafaxine is also an option but is less attractive here because it can raise blood pressure, making it suboptimal in this specific hypertensive context per FDA labeling warnings to monitor for BP changes [^111GYDWw].

> Next, I should integrate nonpharmacologic treatments with medication changes. Cognitive behavioral therapy for insomnia will help consolidate sleep as quetiapine is tapered, and combining psychotherapy with antidepressants increases the likelihood of full recovery in depression, which I should reinforce in counseling and care planning [^112TaqDX]. Hold on, I also need to ensure communication quality and shared decision-making are optimized; using an adaptive care planning approach with structured communication tools like VitalTalk or GeriTalk can align expectations, clarify goals, and improve adherence to the deprescribing and initiation plan [^114tWPgf].

> I need to ensure laboratory and safety monitoring are coherent and accurate. Initially, I noted "baseline and monthly TSH due to quinolone-induced hypothyroidism risk", which is incorrect; wait, let me verify and correct that. The risk pertains to quetiapine-associated hypothyroidism per FDA labeling, not quinolones, and the appropriate plan is baseline and periodic thyroid testing rather than reflexive monthly checks, adjusting frequency based on symptoms or clinical suspicion during and after the taper, which I will document clearly in the chart [^114YQwMB] [^111mS9W3]. I should also reiterate blood pressure monitoring given both the patient's hypertension and the orthostatic risk during quetiapine dose reductions, with closer follow-up in the first three months when medication changes are most active [^111mS9W3] [^114YQwMB].

> Let me summarize the staged plan and correct any internal inconsistencies. Initially, I wrote "Weeks 1–2: continue mirtazapine 7.5 mg nightly; start sertraline 25 mg daily; begin quetiapine taper to mg", and "Weeks 3–4: increase sertraline to 5 mg", which are errors; hold on, I should verify and correct the missing and misstated doses. The intended schedule is Weeks 1–2: mirtazapine 7.5 mg nightly; start sertraline 25 mg daily; reduce quetiapine to 100 mg nightly, Weeks 3–4: increase sertraline to 50 mg daily; reduce quetiapine to 75 mg, Weeks 5–6: consider sertraline 75 mg if needed based on response and tolerability; reduce quetiapine to 50 mg, Weeks 7–8: consider sertraline 100 mg if indicated; reduce quetiapine to 25 mg, Week 9: discontinue quetiapine and reassess sleep and mood, with dose holds if withdrawal or rebound symptoms arise, and alternative SSRI or bupropion considered if sertraline is not tolerated or ineffective by standard intervals [^111GYDWw] [^111mS9W3] [^114YQwMB]. I should confirm that any dose escalations align with clinical response and that shared decision-making is ongoing at each step, with documentation of rationale and patient preferences in the record [^113eCDty].

> Finally, I should ensure the overall plan is guideline-aligned and explicitly justified. Deprescribing quetiapine used off-label for sleep in an older adult with cardiometabolic risk accords with FDA safety warnings regarding falls, hypotension, metabolic changes, anticholinergic burden, and cataracts, while substitution with mirtazapine is supported by ASAM/AAAP guidance for reducing amphetamine-type stimulant use and by its clinical utility for sleep consolidation at low dose; concurrent psychotherapy and structured care planning conform to APA and WHO best practices prioritizing combined treatment and individualized, preference-sensitive care [^111mS9W3] [^114YQwMB] [^114Gruq1] [^112TaqDX] [^111GYDWw] [^113eCDty].

---

Quetiapine is being tapered due to its **metabolic risks** (weight gain, dyslipidemia, hyperglycemia) [^114YQwMB] and **cardiovascular risks** (orthostatic hypotension, QT prolongation) [^111mS9W3], which are concerning in older adults with hyperlipidemia and hypertension. For sleep, **mirtazapine 7.5 mg** is appropriate and may reduce stimulant cravings [^114Gruq1]. For depression, **consider sertraline, bupropion, or venlafaxine**, and add CBT or behavioral activation [^112TaqDX]. Monitor for withdrawal [^114YQwMB], metabolic changes, and cardiovascular effects [^111mS9W3] during the quetiapine taper, and use shared decision-making to align treatment with patient goals [^114tWPgf].

---

## Rationale for tapering quetiapine

Quetiapine is associated with **significant metabolic and cardiovascular risks**, which are particularly concerning in older adults with hyperlipidemia and hypertension [^114YQwMB]:

- **Metabolic risks**: Quetiapine is linked to weight gain, dyslipidemia, and hyperglycemia [^114YQwMB], increasing cardiovascular risk.

- **Cardiovascular risks**: Quetiapine can cause orthostatic hypotension [^111mS9W3] and QT prolongation, increasing fall and arrhythmia risk in older adults.

- **Sedation and cognitive impairment**: Quetiapine's sedative effects [^114YQwMB] can impair cognition and increase fall risk in elderly patients.

Given these risks, **tapering quetiapine** is clinically justified, particularly when it is used primarily for sleep in a patient with hyperlipidemia and hypertension.

---

## Rationale for initiating mirtazapine

For this patient, **mirtazapine 7.5 mg** was chosen for its favorable safety in older adults, potential to reduce stimulant cravings [^114Gruq1], and efficacy in improving sleep:

- **Safety profile**: Mirtazapine has a relatively favorable safety profile in elderly patients, with lower risk of metabolic and cardiovascular side effects compared to quetiapine.

- **Sleep improvement**: Mirtazapine is effective in improving sleep quality, particularly at lower doses (7.5–15 mg).

- **Reduction of stimulant cravings**: Mirtazapine may reduce cravings for methamphetamine and other stimulants [^114Gruq1], supporting recovery efforts.

---

## Alternative pharmacological options for depression

Given the patient's history of methamphetamine and hallucinogen use, an unspecified mood disorder, and a failed trial of Lexapro (escitalopram), **alternative antidepressant options** include:

| **Attribute** | **Sertraline** | **Bupropion** | **Venlafaxine** |
|-|-|-|-|
| Rationale | SSRI with favorable safety profile in elderly patients; Effective for depression and anxiety | NDRI; May reduce stimulant cravings; Minimal sexual side effects | SNRI; Effective for depression and anxiety; May reduce stimulant cravings |
| Considerations | Monitor for hyponatremia and GI side effects [^115jM336] | Avoid in patients with seizure risk or significant anxiety | Monitor blood pressure and withdrawal symptoms |

---

## Non-pharmacological interventions

Non-pharmacological interventions are **essential** for managing depression and substance use disorders. Cognitive-behavioral therapy (CBT) is effective for depression, anxiety [^112TaqDX], and substance use disorders [^113MFoy2]; behavioral activation improves mood and reduces depressive symptoms. Motivational interviewing supports engagement and adherence to treatment [^117Xsqtp], and sleep hygiene education improves sleep quality and reduces reliance on medications.

---

## Monitoring and follow-up plan

A comprehensive monitoring and follow-up plan is **essential** for patient safety and treatment efficacy:

- **Regular monitoring**: Monitor mood symptoms, sleep quality, and substance cravings regularly [^115jM336].

- **Metabolic monitoring**: Monitor weight, lipid profile, and glucose levels during quetiapine taper [^114YQwMB].

- **Cardiovascular monitoring**: Monitor blood pressure and heart rate regularly [^111mS9W3].

- **Patient education**: Educate the patient about potential withdrawal symptoms from quetiapine [^114YQwMB] and side effects of mirtazapine.

- **Shared decision-making**: Engage the patient in shared decision-making to ensure treatment alignment with her preferences and goals [^114tWPgf].

---

## Summary of treatment plan

Taper **quetiapine** gradually due to its metabolic [^114YQwMB] and cardiovascular risks [^111mS9W3], and initiate **mirtazapine 7.5 mg** to improve sleep and potentially reduce stimulant cravings [^114Gruq1]. Consider sertraline, bupropion, or venlafaxine for depression management. Implement CBT, behavioral activation [^112TaqDX], motivational interviewing [^113MFoy2], and sleep hygiene education. Regularly **monitor** mood, sleep, substance cravings, and metabolic and cardiovascular parameters [^114YQwMB], and use shared decision-making to ensure safety and efficacy [^114tWPgf].

---

## References

### SPL drug information for quetiapine fumarate ER [^111mS9W3]. U.S. Food and Drug Administration. High credibility.

Warnings and precautions regarding the use of quetiapine fumarate ER PO (also known as Seroquel XR):

- **Anticholinergic syndrome**: Use caution in patients with urinary retention, prostatic hypertrophy, constipation, or those taking anticholinergic medications.

- **Antipsychotic withdrawal**: Do not discontinue abruptly in any patient.

- **Aspiration pneumonia**: Use caution in elderly patients, particularly those with advanced Alzheimer's disease.

- **Cataract**: Maintain a high level of suspicion, as long-term use of quetiapine has been associated with an increased risk of cataracts.

- **Falls**: Maintain a high level of suspicion, as quetiapine may cause somnolence, orthostatic hypotension, and motor and sensory instability, potentially leading to falls and injuries.

- **Hematologic disorders**: Maintain a high level of suspicion, as quetiapine has been associated with an increased risk of leukopenia, neutropenia, and agranulocytosis.

- **Hyperprolactinemia**: Maintain a high level of suspicion, as quetiapine has been associated with an increased risk of hyperprolactinemia.

- **Hypotension**: Use caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that predispose patients to hypotension (e.g. dehydration, hypovolemia, and treatment with antihypertensive medications).

- **Hypothyroidism**: Maintain a high level of suspicion, as quetiapine has been associated with an increased risk of hypothyroidism. Monitor TSH and fT4 levels.

- **Mania**: Use caution in patients with bipolar disorder. Screen patients for any personal history of mania.

---

### SPL drug information for quetiapine fumarate [^114YQwMB]. U.S. Food and Drug Administration. High credibility.

Warnings and precautions regarding the use of quetiapine fumarate PO (also known as Seroquel):

- **Anticholinergic syndrome**: Use caution in patients with urinary retention, prostatic hypertrophy, constipation, or those taking anticholinergic medications.

- **Antipsychotic withdrawal**: Do not discontinue abruptly in any patient.

- **Aspiration pneumonia**: Use caution in elderly patients, particularly those with advanced Alzheimer's disease.

- **Cataract**: Maintain a high level of suspicion, as long-term use of quetiapine has been associated with an increased risk of cataracts.

- **Falls**: Maintain a high level of suspicion, as quetiapine may cause somnolence, orthostatic hypotension, motor and sensory instability, leading to falls and injuries.

- **Hematologic disorders**: Use caution in patients with leukopenia/neutropenia, including those with a pre-existing low white cell count (WBC) and a history of drug-induced leukopenia/neutropenia.

- **Hyperprolactinemia**: Maintain a high level of suspicion, as quetiapine has been associated with an increased risk of hyperprolactinemia.

- **Hypotension**: Use caution in patients with cardiovascular or cerebrovascular disease, dehydration/hypovolemia, or those taking antihypertensive agents.

- **Hypothyroidism**: Maintain a high level of suspicion, as quetiapine has been associated with an increased risk of hypothyroidism. Monitor TSH and fT4 levels.

- **Mania**: Use caution in patients with bipolar disorder. Screen patients for any personal or family history of bipolar disorder before initiating quetiapine.

- **Metabolic changes**: Maintain a high level of suspicion, as quetiapine has been associated with various metabolic changes.

---

### APA clinical practice guideline for the treatment of depression across three age cohorts [^112TaqDX]. APA (2019). High credibility.

Regarding medical management for major depressive disorder, especially in initial therapy, the APA 2019 guidelines recommend considering the following options when selecting treatments:

- **Behavioral therapy**: Prefer this over antidepressant medication alone for initial therapy.

- **Cognitive therapy plus antidepressant medication**: Combining these treatments is advised to improve the likelihood of full recovery.

---

### Mental health gap action programme (mhGAP) guideline for mental, neurological and substance use disorders [Internet] [^111GYDWw]. Geneva: World Health Organization (2023). High credibility.

Regarding the medical management of major depressive disorder, specifically concerning initial therapy, the WHO 2023 guidelines recommend considering the following antidepressants for adults with moderate-to-severe depression:

- Citalopram
- Escitalopram
- Fluoxetine
- Fluvoxamine
- Paroxetine
- Sertraline
- Amitriptyline

---

### The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder [^114Gruq1]. Journal of Addiction Medicine (2024). High credibility.

Regarding medical management for stimulant use disorder, specifically with respect to antidepressants, the AAAP/ASAM 2024 guidelines suggest offering mirtazapine to promote reduced use of amphetamine-type stimulants in patients with amphetamine-type stimulant use disorder.

---

### Early use of long-acting injectable antipsychotics in bipolar disorder type I: An expert consensus [^114hNxb6]. Bipolar Disorders (2025). High credibility.

- **Accessibility challenges — infrastructure and maintenance logistics**: The requirement for additional resources and infrastructure for long-acting injectables (LAIs) compared to oral medications can be a key accessibility barrier. Healthcare facilities, such as clinics and hospitals with staff experienced in caring for patients with psychiatric disorders, are traditionally required to administer LAIs. These facilities should exist within manageable distances of patients and be open at convenient times, with adequate staffing levels being critical. In regions where these needs are unmet, especially in lower-resourced settings, non-attendance likelihood increases. While home visits for injections may be an alternative, they can be limited by low staffing levels or other barriers. The employment of pharmacists to deliver LAIs represents an important advancement in access, as pharmacies are among the most ubiquitous and accessible healthcare settings.

	- The post-COVID-19 healthcare landscape may also pose a barrier to clinicians adopting new treatment strategies. During the COVID-19 pandemic, the administration of LAIs was suspended in some areas as it was deemed an "elective" procedure. This suspension led the American Psychiatric Association to issue specific COVID-19 pandemic guidance on LAI administration, encouraging clinics, hospitals, and other medical facilities to include the ongoing use of LAIs for patients with high-risk chronic illness as a necessary procedure, noting the risks of treatment withdrawal.

---

### The multidimensionality of sleep quality and its relationship to fatigue in older adults with painful osteoarthritis [^113Pode8]. Osteoarthritis and Cartilage (2010). Low credibility.

To evaluate subjective sleep quality and its relationship to fatigue in older adults with osteoarthritis (OA), a study was conducted using a community cohort with hip or knee OA. Subjective sleep quality was measured using the Pittsburgh Sleep Quality Index (PSQI) and fatigue was assessed through the Profile of Mood States - Fatigue subscale (POMS-F).

Correlates of sleep quality and fatigue were determined by standardized interviews, which included:

- **Socio-demographics**: Information about the participants' social and demographic background.
- **OA Severity**: Assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) summary score.
- **Comorbidity and depression**: Evaluated using the Center for Epidemiologic Studies Depression Scale (CES-D).
- **Other Factors**: Stressful life events, daytime napping, symptoms of restless legs syndrome (RLS), and prior sleep disorder diagnoses.

Logistic regression was employed to examine correlates of poor sleep (PSQI score > 5). Linear regression evaluated the relationship between poor sleep and fatigue and assessed the effect of napping on this relationship.

In the study of 613 respondents, the average age was 78 years, with 78% being female. Among the participants, 11% had concomitant fibromyalgia, and 26% had three or more comorbid conditions. The findings indicated moderate OA severity, with 70% reporting poor sleep, 25% meeting the criteria for RLS, and 6.5% reporting a diagnosed sleep disorder. Independent correlates of poor sleep included:

- Greater arthritis severity, with an adjusted odds ratio (OR) per unit increase in WOMAC score of 1.03 (P < 0.0001).
- Having three or more comorbid conditions (adjusted OR = 1.88; P = 0.03).
- Depressed mood, with an adjusted OR per unit increase in CES-D score of 1.09 (P < 0.0001).
- RLS, with an adjusted OR of 1.87 (P = 0.02).

The analysis controlled for previously reported fatigue correlations.

---

### Mental health gap action programme (mhGAP) guideline for mental, neurological and substance use disorders [Internet] [^113eCDty]. Geneva: World Health Organization (2023). High credibility.

Regarding the medical management of schizophrenia, specifically concerning the initiation of antipsychotic therapy, WHO 2023 guidelines recommend initiating an antipsychotic medication such as aripiprazole, chlorpromazine, haloperidol, olanzapine, paliperidone, quetiapine, or risperidone in adult patients with psychotic disorders, including schizophrenia. It is crucial to carefully balance effectiveness, side effects, and individual preferences.

---

### Process evaluation of a tailored intervention to reduce inappropriate psychotropic drug use in nursing home residents with dementia [^112TR8ZA]. BMC Geriatrics (2021). Low credibility.

Several barriers were common, such as reorganizations, staff shortages and turnover, and communication issues within and between disciplines (e.g. too little contact, criticizing each other, or not being receptive to feedback). Another perceived barrier was the use of self-directed teams that had responsibilities and duties assigned without a formal lead. Some nursing homes (NHs) embraced change whereas others seemed more reluctant; for example, it was observed that some multidisciplinary team (MPT) members questioned every suggestion or assumed that colleagues would not adhere to agreements made. Limited self-reflection was also mentioned, with respondents indicating that MPT members and nursing home staff sometimes found it hard to accept that the level of psychotropic drug use (PDU) in their NH was high, despite feedback and evidence to the contrary.

Time pressure interfered with implementation in other instances, and in some cases, NH management did not grant their staff the time needed to complete the project; however, several respondents indicated that the issue of time constraints, whether perceived or real, was about setting priorities. Implementation was facilitated when NHs developed a vision on PDU with sufficient alternatives, as it allowed them to build on a basic level and focus on fine-tuning agreements. Levels of innovative power were different among NHs, and it appeared that those accustomed to participating in research had an easier time with implementation. It was also easier to implement the RID intervention when it could be integrated with other projects, but this was at the cost of the mult.

---

### Fluvoxamine maleate [^115YWijN]. U.S. Food and Drug Administration (2023). High credibility.

Before taking Fluvoxamine Maleate Tablets, it is important to discuss the following with your healthcare provider:

- **Medications you are currently taking**:
	- Monoamine oxidase inhibitors (MAOIs) such as Emsam (selegiline), Nardil (phenelzine), or Parnate (tranylcypromine).
	- **Mellaril ® (thioridazine)**: Used to treat mental or mood problems.
	- **Zanaflex (tizanidine)**: Used to treat spasticity (a condition where muscles keep tightening and cramping).
	- **Orap (pimozide)**: Used to treat Tourette Syndrome (a brain condition causing tics).
	- **Lotronex (alosetron)**: Used to treat a condition with diarrhea, continuing stomach pain, cramps, and bloating.
	- **Triptans**: Used to treat migraine headaches.
	- Medicines used to treat mood, anxiety, psychotic, or thought disorders, including tricyclics, lithium, SSRIs, SNRIs, or antipsychotics.
	- Opioids such as tramadol, fentanyl, meperidine, methadone, or other similar drugs.
	- **Benzodiazepines**: Used to reduce anxiety, stress, emotional upset, or seizures; helps with sleep, alcohol withdrawal; reduces restlessness; and relaxes muscles.
	- **Clozapine**: Used to treat mental disorders.
	- **Mexiletine**: Used to treat abnormalities in heart rhythm.
	- **Theophylline**: Used to treat swollen air passages in your lungs and to relax the muscles in your chest to ease shortness of breath, often to treat asthma.
	- Warfarin and other drugs that affect blood clotting.
	- **Diuretics**: Used to treat high blood pressure, congestive heart failure, or swelling.
	- Over-the-counter supplements such as tryptophan or St. John's Wort.

- **Existing health conditions**:
	- If you have liver problems.
	- If you have kidney problems.

---

### SIGN 143 diagnosis and management of epilepsy in adults: A national clinical guideline [^1123iNGS]. SIGN (2015). High credibility.

The SIGN 2015 guidelines recommend obtaining several diagnostic investigations during the initial evaluation of status epilepticus. It is advised to acquire a complete blood count (CBC), urea and electrolytes, liver function tests (LFTs), calcium, glucose, clotting profiles, and antiepileptic drug levels. Additionally, store the collected blood for later tests and measure blood gases to assess the extent of acidosis.

---

### SPL drug information for quetiapine fumarate ER [^115y3BcE]. U.S. Food and Drug Administration. High credibility.

Regarding the use of quetiapine fumarate ER PO (also known as Seroquel XR) in patients with chronic liver disease of any severity, start at a dose of 50 mg/day and titrate in increments of 50 mg/day.

---

### The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update [^113ejSCV]. Journal of Addiction Medicine (2020). High credibility.

Regarding medical management for opioid use disorder, particularly with respect to methadone, the ASAM 2020 guidelines recommend using a daily dose of 60–120 mg of methadone following initial withdrawal stabilization. It is recognized that some patients may respond to lower doses, while others may require higher doses. Methadone titration should be individualized based on a careful assessment of the patient's response, with the general recommendation being that doses should not be increased daily. Consider increasing methadone by no more than 10 mg approximately every 5 days, based on the patient's symptoms of opioid withdrawal or sedation.

---

### Quetiapine may reduce hospital admission rates in patients with mental health problems and alcohol addiction [^116FQSti]. BMJ Case Reports (2013). Low credibility.

A 64-year-old man presented with a 40-year history of chronic alcohol excess. On average, he had six hospital admissions a year due to alcohol-related problems over at least a 10-year period. In 2009, he considered reducing his alcohol intake. He was noted to have mood disturbances and was seen by a psychogeriatrician, who diagnosed bipolar disorder. He tried various bipolar medications, including lithium and sodium valproate, which were unsuccessful. He was then started on quetiapine 600 mg a day in divided doses. Subsequently, this not only controlled the bipolar disorder but also resulted in a significant reduction in alcohol intake. He now shares a bottle of wine with his wife, whereas in the past, he was consuming a bottle of scotch daily. This case illustrates the benefits of quetiapine in assisting with this man's addiction to alcohol.

---

### Marplan [^1163EzWY]. U.S. Food and Drug Administration (2023). High credibility.

Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Marplan and should counsel them in its appropriate use. A patient medication guide titled "Antidepressant Medications, Depression and Other Serious Mental Illness, and Suicidal Thoughts and Actions" is available for Marplan. The prescriber or health professional should instruct patients, their families, and their caregivers to read the medication guide and assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the medication guide and to obtain answers to any questions they may have. The complete text of the medication guide is reprinted at the end of this document.

Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Marplan.

- **Signs of clinical worsening and suicide risk**: anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, suicidal ideation

Patients, their families, and their caregivers should be encouraged to be alert to the emergence of these symptoms, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt.

---

### Early use of long-acting injectable antipsychotics in bipolar disorder type I: An expert consensus [^112AMi1b]. Bipolar Disorders (2025). Low credibility.

This consensus discussed the benefits of long-acting injectables (LAIs) in the management of bipolar disorder type I (BP-I), particularly during the early stages of the disease. It identified barriers to overcome while providing potential solutions to aid key stakeholders in making informed treatment decisions. The main consensus recommendations were as follows:

- **Consensus recommendation 1**: It is important to move away from the preconceived notion that LAIs can be used only for patients with the most severe BP-I. Communication of potential early benefits is key to avoiding the perpetuation of stigmatization of patients.

- **Consensus recommendation 2**: If antipsychotic therapy is included in the pharmacologic treatment plan, LAIs should be initiated as early as possible in the disease course, ideally at the first manic episode, to aid in improving long-term outcomes.

- **Consensus recommendation 3**: A collaborative focus on the direct involvement of all stakeholders in the decision-making process should support a more positive patient experience, better care quality, and improved health outcomes, such as reduced relapse, hospitalization, and burden on healthcare systems.

- **Consensus recommendation 4**: With careful outcome tracking and a systematic approach to medication changes, logical and strategic combination pharmacotherapy can be designed to minimize unnecessary exposure to redundant, ineffective, or otherwise superfluous psychotropic agents.

- **Consensus recommendation 5**: The generation of additional evidence for the use of LAIs early in the disease course is essential to support these approaches.

---

### Venlafaxine hydrochloride [^113bpqgs]. U.S. Food and Drug Administration (2021). High credibility.

Read the Medication Guide that comes with your or your family member's antidepressant medicine. This guide specifically addresses the risk of suicidal thoughts and actions associated with antidepressant medications. Discuss with your healthcare provider all risks and benefits of treatment with antidepressant medicines, as well as all available treatment options for depression or other serious mental illnesses.

- **Taking monoamine oxidase inhibitors (MAOI)**: Consult your healthcare provider or pharmacist to determine if you are taking an MAOI, including the antibiotic linezolid. Do not take an MAOI within 7 days of stopping venlafaxine hydrochloride extended-release tablets unless directed by your physician. Similarly, do not start venlafaxine hydrochloride extended-release tablets if you have stopped taking an MAOI in the past 2 weeks unless instructed by your physician.

- **Monitor changes in mood and behavior**: Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is particularly crucial when starting an antidepressant or when there is a change in dosage.

- **Communicate with healthcare providers**: Contact your healthcare provider immediately to report new or sudden changes in mood, behavior, thoughts, or feelings. Keep all scheduled follow-up visits with your healthcare provider and call them between visits if you have any concerns about symptoms.

Never abruptly stop taking an antidepressant without professional guidance.

---

### SPL drug information for quetiapine fumarate [^113QoXZG]. U.S. Food and Drug Administration. High credibility.

Regarding the use of quetiapine fumarate PO (also known as Seroquel) in patients with chronic liver disease of any severity, start at a dose of 25 mg/day and titrate in increments of 25–50 mg/day.

---

### Talvey [^1179wAym]. U.S. Food and Drug Administration (2024). High credibility.

Talvey can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions [see Adverse Reactions (6.1)]. In the clinical trial, CRS occurred in 76% of patients who received Talvey at the recommended dosages. Grade 1 CRS occurred in 57% of patients, Grade 2 in 17%, and Grade 3 in 1.5%. ReCRS occurred in 30% of patients. Most events occurred following step-up dose 1 (29%) or step-up dose 2 (44%) at the recommended dosages. CRS occurred in 33% of patients with step-up dose 3 in the biweekly dosing schedule (N = 153). CRS occurred in 30% of patients with the first 0.4 mg/kg treatment dose and in 12% of patients treated with the first 0.8 mg/kg treatment dose. The CRS rate for both dosing schedules combined was less than 3% for each of the remaining doses in Cycle 1 and less than 3% cumulatively from Cycle 2 onward. The median time to onset of CRS was 27 (range: 0.1 to 167) hours from the last dose, and the median duration was 17 (range: 0 to 622) hours. Clinical signs and symptoms of CRS include, but are not limited to, pyrexia, hypotension, chills, hypoxia, headache, and tachycardia. Potentially life-threatening complications of CRS may include cardiac dysfunction, acute respiratory distress syndrome, neurologic toxicity, renal and/or hepatic failure, and disseminated intravascular coagulation (DIC).

Initiate Talvey therapy with step-up dosing and administer pre-treatment medications (corticosteroids, antihistamines, and antipyretics) prior to each dose of Talvey in the step-up dosing schedule to reduce the risk.

---

### Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders [^111GrprL]. BMC Psychiatry (2014). High credibility.

Regarding the medical management for obsessive-compulsive disorder, particularly concerning antipsychotics, the 2014 guidelines recommend considering quetiapine or topiramate as second-line adjunctive therapy for OCD.

---

### Motion sickness diagnostic criteria: Consensus document of the classification committee of the Bárány Society [^1137RXQN]. Journal of Vestibular Research (2021). High credibility.

The following constitutes key background information on motion sickness:

- **Definition**: Motion sickness is a common condition that results from an adverse physiological response to real or perceived motion stimuli. It typically involves low-frequency vertical, lateral, angular, or rotary motion, occurring during travel by sea, land, air, or immersion in virtual reality.

- **Pathophysiology**: The pathophysiology of motion sickness involves a conflict between expected and actual interactions among vestibular, visual, and proprioceptive inputs. When vestibular signals about motion and changes in position are inconsistent with visual or proprioceptive inputs, a mismatch can occur, triggering the autonomic nervous system and activating the vomiting center in the brainstem.

- **Epidemiology**: The prevalence of motion sickness in school-age children and young adults is estimated at 35–43% and 25%, respectively. Seasickness is the most frequent and notable form of motion sickness.

- **Risk factors**: Risk factors for motion sickness include individual susceptibility, which can vary greatly among people, and certain conditions or factors such as age (children and young adults are more susceptible), gender (women are more susceptible than men), and certain medications that can affect the vestibular system. Additionally, the type and intensity of motion can also influence the likelihood of experiencing motion sickness.

- **Disease course**: The clinical course of motion sickness typically begins with a feeling of unease, followed by cold sweats and dizziness, progressing to nausea and, in severe cases.

---

### An interesting case of late age at onset of narcolepsy with cataplexy [^111Bfq26]. Journal of Clinical Sleep Medicine (2014). Low credibility.

The usual age at onset of narcolepsy with cataplexy is in the second or third decade. In cases of late-onset narcolepsy with cataplexy, symptoms are usually mild, with relatively less severe daytime sleepiness and less frequent cataplexy. Here, we present a case of narcolepsy with cataplexy with the onset of symptoms around sixty years of age. This case is unique, with severe daytime sleepiness both by subjective report and on objective Multiple Sleep Latency Test, and includes multiple cataplexy episodes in a day.

---

### Implementing practice guidelines: Lessons from public mental health settings [^111DmzC2]. The Journal of Clinical Psychiatry (2007). Low credibility.

There is evidence that state-of-the-art psychiatric treatments are not being translated into community settings, resulting in the de facto denial of up-to-date psychiatric care for many Americans with mental illness. Although multiple models of evidence-based care exist, little is known about how to disseminate information regarding these models to clinicians in real-world practice.

Suggested solutions have included the use of published practice guidelines, such as the American Psychiatric Association Practice Guidelines and the Expert Consensus Guidelines, or algorithm-based programs such as the Texas Medication Algorithm Project. Unfortunately, the real-world utility of practice guidelines tends to be limited because their implementation depends entirely on practitioner self-motivation. Similarly, the use of algorithm-based programs may be limited by their pervasive high specificity, practitioner resistance, and various patient misperceptions.

Another solution is the implementation of evidence-based practices (EBPs), such as the Substance Abuse and Mental Health Services Administration (SAMHSA) EBPs. However, states' use of the SAMHSA EBPs has been hampered by a misalignment of the funding structure, a lack of information regarding EBPs, high costs to train and supervise staff, staff turnover, and a lack of resources.

As a result, federal and clinical/professional agencies have called for a change in the nation's mental health care delivery system, supplying persuasive arguments for the economic and clinical superiority of integrated care models.

---

### Fluvoxamine maleate [^115J71km]. U.S. Food and Drug Administration (2023). High credibility.

Advise the patient to read the FDA-approved patient labeling (Medication Guide). Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with fluvoxamine maleate tablets and should counsel them in the appropriate use. A patient Medication Guide titled "Antidepressant Medicines, Depression and other Serious Mental Illnesses, and Suicidal Thoughts or Actions" is available for fluvoxamine maleate tablets. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.

Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking fluvoxamine maleate tablets.

- **Psychological changes**: Anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity.
- **Movement and behavioral changes**: Akathisia (psychomotor restlessness), hypomania, mania.
- **Mood changes**: Other unusual changes in behavior, worsening of depression, and suicidal ideation.

Patients and their caregivers should be especially observant for these symptoms early during antidepressant treatment and when the dose is adjusted up or down.

---

### The Canadian Coalition for Seniors' Mental Health Canadian clinical practice guidelines for assessing and managing behavioural and psychological symptoms of dementia (BPSD) [^1165H29z]. Canadian Geriatrics Journal (2025). High credibility.

Regarding the medical management of behavioral and psychological symptoms of dementia, particularly concerning antipsychotics, the CCSMH 2025 guidelines recommend considering the use of quetiapine for treating severe agitation that is refractory to other pharmacological treatments, or if these are not tolerated due to extrapyramidal side effects, in patients with Alzheimer's disease and related dementias.

---

### A useful and sustainable role for n-of-1 trials in the healthcare ecosystem [^115QhJtK]. Clinical Pharmacology and Therapeutics (2022). High credibility.

Clinicians, as allies of their patients and seeking evidence for the treatments they prescribe, are generally attracted to the idea of n-of-1 trials. If these trials can be practically and efficiently executed without disrupting the process and economics of patient care, clinicians may welcome the opportunity for structured shared decision-making and the engagement of the broader care team. However, the logistics and economics of the approach must be attractive for adoption in routine clinical practice. This will require easy-to-use processes and platforms to implement n-of-1 studies and coverage of expenses by healthcare payers and/or sponsors.

Clinical researchers, including clinical epidemiologists, have long been attracted to type 1 n-of-1 trials in chronic conditions. These trials support rigorous trial processes to reveal which treatments work best and, when combined, reduce sample size requirements because participants serve as their own controls. More recently, researchers have utilized type 2 n-of-1 trials to assess cutting-edge, highly personalized treatments. As a potential addition to the drug development and evaluation toolkit, the use of n-of-1 trials highlights the need for standard processes and platforms, similar to those used for phases I, II, and III trials, including meeting regulatory requirements to bring a new treatment to the public. This would greatly facilitate the use of these studies by academic and industry researchers. For the structuring of clinical research practices to happen, there will need to be support from the stakeholders who derive benefits from these practices.

---

### Epkinly [^115ZE455]. U.S. Food and Drug Administration (2024). High credibility.

Relapsed or refractory follicular lymphoma (FL) is associated with cytokine release syndrome (CRS), which occurred in 49% (42/86) of patients receiving Epkinly at the recommended 3-step up dosage schedule in EPCORE NHL-1. Specifically, Grade 1 CRS occurred in 45% and Grade 2 in 9% of patients. Recurrence of CRS (ReCRS) occurred in 23% of patients. Notably, 88% of all CRS events occurred during Cycle 1. In Cycle 1, CRS events were observed in 14% of patients after the 0.16 mg dose on Cycle 1 Day 1, in 7% after the 0.8 mg dose on Cycle 1 Day 8, in 17% after the 3 mg dose on Cycle 1 Day 15, and in 49% after the 48 mg dose on Cycle 1 Day 22. The median time to onset of CRS from the most recent administered Epkinly dose across all doses was 59 hours (range: 0.1 to 7 days). Specifically, the median time to onset after the first full 48 mg dose was 61 hours (range: 0.1 to 7 days). Importantly, CRS resolved in 100% of patients, with a median duration of CRS events of 2 days (range: 1 to 14 days).

Patients with LBCL and FL who experienced CRS exhibited signs and symptoms such as pyrexia, hypotension, hypoxia, dyspnea, chills, and tachycardia. Neurological adverse reactions associated with CRS occurred in 2.5% of patients with LBCL and 4.7% of patients with FL. In patients with LBCL, neurological adverse reactions included headache, confusional state, tremors, dizziness, and ataxia. For those with FL, the reactions included headache and dizziness.

Therapy should be initiated according to the Epkinly step-up dosage schedule. It is important to administer pretreatment medications to reduce the risk of CRS and diligently monitor patients for potential CRS following Epkinly administration.

---

### Global initiative for asthma strategy 2021: Executive summary and rationale for key changes [^111RDuHV]. American Journal of Respiratory and Critical Care Medicine (2022). High credibility.

When choosing the track and starting step for initial asthma treatment, consider not only the patient's symptoms and risk of exacerbations but also practical issues, including medication access (availability and cost), inhaler technique, likely adherence, and patient preferences. Before starting, record evidence for the diagnosis of asthma, assess the patient's symptom control and risk factors, including lung function, and ensure they can use the inhaler correctly. Provide education and skills training, and schedule a follow-up visit to assess the response.

During ongoing treatment, medication may be adjusted up or down within the same track (i.e. with the same reliever) or may be switched between tracks, depending on patient needs. However, for patients prescribed as-needed-only ICS–formoterol (Steps 1–2) or MART (Steps 3–5), beware of risks to the patient if their ICS–formoterol is switched without consultation (e.g. in health systems where medication substitution by pharmacists or nurses is permitted) to a combination nonformoterol ICS–LABA, as these are not suitable for as-needed use.

When good asthma control has been achieved and maintained for 2–3 months, consider stepping down to find the lowest effective step. Do not completely withdraw ICS, except if needed temporarily while confirming the diagnosis of asthma. Adults and adolescents with well-controlled asthma while on daily low-dose controller therapy can step down to either as-needed ICS–formoterol.

---

### Designing clinically useful psychopharmacological trials: Challenges and ways forward [^117FcoYu]. The Lancet Psychiatry (2022). Low credibility.

The clinical guidelines that underpin the use of drugs for mental disorders are informed by evidence from randomised controlled trials (RCTs). RCTs are performed to obtain marketing authorisation from regulators. The methods used in these RCTs could be appropriate for early phases of drug development because they identify drugs with important harms and drugs that are efficacious for specific health problems and populations. However, RCTs done before marketing authorisation do not tend to address clinical questions that concern the effectiveness of a drug in heterogeneous and comorbid populations, the optimisation of drug sequencing and discontinuation, or the comparative benefits and harms of different drugs that could be used for the same health problem.

This review proposes an overview of some shortcomings of RCTs, at an individual level and at the whole portfolio level, and identifies some methods in planning, conducting, and carrying out analyses in RCTs that could enhance their ability to support therapeutic decisions. These suggestions include identifying patient-important questions to be investigated by psychopharmacological RCTs; embedding pragmatic RCTs within clinical practice to improve generalisability to target populations; collecting evidence about drugs in overlooked populations; developing methods to facilitate the recruitment of patients with mental disorders and to reduce the number of patients who drop out using specific methods; using core outcome sets to standardise the assessment of benefits and harms; and systematically recording serious objective outcomes.

---

### Living concussion guidelines: Guideline for concussion & prolonged symptoms for adults 18 years of age or older: 2023 April update [^114jdYgu]. ConcussionsOntario (2023). High credibility.

Regarding follow-up and surveillance for concussion, more specifically with respect to the evaluation of prolonged symptoms, LCG 2023 guidelines recommend reviewing currently prescribed medications (and adherence), over-the-counter medications/supplements, and substance use, including alcohol, cannabis, and other drugs.

---

### Challenges to delivering evidence-based management for long COVID [^1167jXYU]. BMJ Evidence-Based Medicine (2023). High credibility.

Government and non-government organizations, as well as academic institutions, have taken steps to support, fund, and conduct research on repurposed drugs, newly developed medications, and non-pharmacological interventions for managing long COVID. These efforts aim to alleviate symptoms and optimize the function and quality of life for patients with post-COVID-19 conditions. Additionally, these organizations disseminate research findings to raise awareness and understanding among the public and health professionals about post-COVID-19 symptoms. Patient networks are also influencing the research agenda and accelerating progress in this field.

Most trials recruit patients with persistent symptoms following a specific time range, usually three or more months since acute infection, focusing on fatigue, asthenia, and respiratory symptoms. Frequently reported outcomes include symptom improvement, generally assessed with specific scales, and health-related quality of life.

This has led to the implementation of large-scale trials, such as the US National Institutes of Health $1.5 billion RECOVER study and the UK STIMULATE-ICP study. Due to the multiple pathogenesis and varied clinical presentations of post-COVID-19 condition, medical management is vast and tailored at an individual level. Consequently, this has led to the production of both small-scale and large-scale clinical trials, as reflected in the International Clinical Trial Registry (ICTRP). As of February 2023, 444 interventional studies and 342 observational studies on post-COVID/long COVID were registered in the ICTRP. There were 314 randomized trials from 36 countries.

---

### Practice guideline for the treatment of patients with major depressive disorder (third edition) [^115jM336]. APA (2010). High credibility.

Regarding the medical management of major depressive disorder, the APA 2010 guidelines recommend considering the effects of prescribed psychotropic medications on the patient's general medical conditions, as well as the impact of interventions for such disorders on the patient's psychiatric condition.

---

### Biallelic sequence and structural variants in RAX2 are a novel cause for autosomal recessive inherited retinal disease [^1116Eb5a]. Genetics in Medicine (2019). Low credibility.

Fundus and optical coherence tomography (OCT) imaging in patients with RAX2-associated ARRP is depicted in Figure 1. Images (a – f) display fundus views, and (g – l) show OCT images of patients I-VI (left eye), which exhibit features characteristic of retinitis pigmentosa. Notable features include varying degrees of pigmentation and a general preservation of foveal structure.

Table 1 provides an overview of clinical findings in RAX2-associated ARRP.

Patient I is a 37-year-old Belgian female with simplex retinitis pigmentosa (RP), diagnosed at age 34, experiencing night blindness and a reduced visual field. Patient II, diagnosed with simplex RP in his mid-teens, began experiencing night blindness at around age five. Patient III, a 58-year-old female of Italian descent, was diagnosed with simplex RP at age 35, with night blindness onset at 51. Her medical history is clear of systemic conditions, and family history is negative.

Patient IV, a 61-year-old Spanish female, has a history of glaucoma and cataracts, leading to right eye enucleation in 2009. She was diagnosed with simplex RP at age 48, experiencing night blindness, visual field constriction, and loss of visual acuity. Her family originates from a genetically isolated village in northern Spain. Patient V, a 60-year-old British female, and her brother (Patient VI) began exhibiting mild RP symptoms in their mid-40s; their parents are unrelated.

---

### The burden of diseases, injuries, and risk factors by state in the United States, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 [^116hjWjK]. Lancet (2024). Low credibility.

In addressing the disease burden in the United States, it is crucial to acknowledge the growing issue of drug use and addiction, a problem that has been largely exacerbated by the over-prescription of pain medications. The failure of pain clinics and other health providers to regulate the distribution of these medications has led to a widespread opioid crisis, resulting not only in increased addiction rates but also a substantial strain on our healthcare system. In recent years, the increasing availability of cheaper, more potent alternatives such as fentanyl has worsened the problem even further.

The policies needed to slow and ultimately reverse drug use trends in the United States include tightening regulations on prescription practices, investing in effective prevention and treatment programs, and fostering a greater understanding of addiction as a public health concern rather than a criminal issue. Similarly, US authorities must redouble their efforts to control the flow of illegal drugs, which can be aided through international cooperation and intelligence-sharing among law enforcement agencies. By proactively addressing the root causes of drug addiction and implementing evidence-based policies, we can reverse the growing burden of drug use on Americans' health and avert an even more challenging future.

Mental health remains a stigmatized and under-addressed issue, and in the United States, it is often segregated from physical health at both the programmatic level — with the US CDC focusing on physical health and SAMHSA focusing on mental health — and the patient level, with limited coordination between primary care and mental health services.

---

### The effect of continuous positive airway pressure on nocturia in patients with obstructive sleep apnea syndrome [^112h6oiC]. Neurourology and Urodynamics (2020). Low credibility.

The prevalence of nocturia in patients with obstructive sleep apnea syndrome (OSAS) who received continuous positive airway pressure (CPAP) treatment was studied, as well as the effect of CPAP treatment on nocturia.

- **Methods**: All patients that were referred to the pulmonology department of a large teaching hospital in the Netherlands and received a CPAP mask for OSAS were interviewed and invited to take part in the study (N = 274). After informed consent, all patients were asked about the number of nocturia episodes before and after CPAP.

- **Results**: In this prospective analysis, 274 patients (190 male and 84 female) were included. The mean age was 60.3 years (SE = 0.7). Sixty-four patients (23.4%) reported no nocturia episodes before CPAP, and 210 patients (76.4%) reported one or more nocturia episodes. Treatment of OSAS with CPAP reduced nocturia by one or more episodes per night in 42.3% of the patients. Clinically relevant nocturia (two or more voids per night) was reduced from 73.0% to 51.5%. There were no statistically significant gender differences.

- **Conclusion**: The prevalence of nocturia in patients diagnosed with OSAS is 75.8% in both sexes. After treatment with CPAP, almost half of the patients experienced a decrease in the nocturia frequency by one or more voids. Clinically relevant nocturia was reduced by one-third after CPAP. CPAP not only reduced the number of voids during the night but also improved the associated quality of life.

---

### Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment [^116PZ2YA]. Schizophrenia Bulletin (2009). High credibility.

Findings from two pivotal government-funded studies of comparative antipsychotic effectiveness undermine assumptions about the marked superiority of the more expensive second-generation "atypical" medications compared to the less expensive first-generation "typical" drugs. Because this assumption was the basis for the almost universal recommendation that these newer antipsychotics be used preferentially, resulting in a ten-fold increase in state governmental expenditures on this class of medications over the past decade, a reassessment of policy is called for.

To address this issue, the Medical Directors Council of the National Association of State Mental Health Program Directors critically reviewed findings of these studies in the context of other data. They considered policy implications in light of the state government's obligations to make available the best possible and individually optimized treatment that is cost-effective. The Medical Directors Council unanimously adopted a set of recommendations to promote appropriate access, efficient utilization, and best practice use.

We present our policy statement, in which we provide a succinct background, articulate general principles, and describe a set of four broad recommendations. We then summarize our understanding of the state of knowledge about comparative antipsychotic effectiveness, best antipsychotic practice, and considerations for state policy that represent the basis of our position statement.

---

### Portia [^112uiKJu]. U.S. Food and Drug Administration (2025). High credibility.

Day 1 start: If your doctor advised you to take your first pill on the first day of your period, you should begin with a "Day 1 start". Take one pill daily, following the order in the pill dispenser, at the same time each day, for 28 days. To remove your pill from the dispenser, press the pill through the hole at the bottom. After finishing the last pill on Day 28 of your pill dispenser, start a new pack on the same day of the week, regardless of whether you are having your period.

- **What should I do if I miss any Portia pills**:

	- **If you miss 1 pill in weeks 1, 2, or 3**: Take it as soon as you remember. Then, take the next pill at your regular time, which may mean taking two pills in one day. Continue with one pill daily until you finish the pack. No back-up birth control is needed if you have sex.

	- **If you miss 2 pills in week 1 or week 2**: Take the two missed pills as soon as possible, and take two pills the next day. Continue taking one pill daily until you finish the pack. Use a non-hormonal birth control method, such as a condom or spermicide, as a back-up if you have sex in the first seven days after missing your pills.

---

### The mucormycete-host interface [^111NYkxE]. Current Opinion in Microbiology (2017). Low credibility.

Mucormycosis is a fungal infection characterized by fulminant angioinvasion, which leads to high morbidity and mortality in susceptible individuals. Major predisposing conditions include uncontrolled diabetes, neutropenia, malignancies, receipt of a transplant, and traumatic injury [1]. Over the past decade, mucormycosis has emerged as a significant fungal infection due to the increase in patient groups presenting these predisposing conditions and advances in medical diagnostics [2–4]. However, effective clinical interventions to treat mucormycosis remain lacking. This is primarily due to a limited understanding of the pathogenesis of mucormycosis. In this paper, we discuss selected aspects of interactions at the mucormycete-host interface. We will highlight open questions that could guide future research directions for investigations into the pathogenesis of mucormycosis and potential innovative therapeutic approaches.

---

### BAP updated guidelines: Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP [^113PYr4Z]. Journal of Psychopharmacology (2012). High credibility.

Regarding the medical management of benzodiazepine use disorder, specifically in terms of adjunctive therapy, the BAP 2012 guidelines recommend considering additional pharmacotherapy, such as antidepressants, melatonin, valproate, and flumazenil, on an individual basis to enhance the effectiveness of gradual dose reduction.

---

### How do you design randomised trials for smaller populations? A framework [^114xSudk]. BMC Medicine (2016). Low credibility.

Exploring less common approaches to reducing sample size, we now consider some less standard approaches to bringing the sample size requirements closer to the numbers it is feasible to recruit in a reasonable time frame.

- **Step 3: Relaxing α by a small amount, beyond traditional values**: The much-criticised 5% significance level is used widely in much applied scientific research but is an arbitrary figure. It is extremely rare for clinical trials to use any other level. It may be argued that this convention has been adopted as a compromise between erroneously concluding that a new treatment is more efficacious and undertaking a trial of an achievable size and length. Settings where traditionally sized trials are not possible may be just the area where researchers start to break this convention, for good reason.

In considering the type I error, it is critical to consider the question: "What are the consequences of erroneously deciding to use a new treatment routinely if it is truly not better?" Taking the societal perspective as before, we might consider the probability of making a type I error, thus erroneously burdening patients with treatments that do not improve outcomes or even worsen them, while potentially imposing unnecessary toxicity.

First, for conditions where there are only enough patients available to run one modestly sized randomised trial in a reasonable time frame, research progress will be relatively slow, and making a type I error may be less of a concern than a type II error. In contrast, making several type I errors in a common disease could lead to practical challenges…

---

### Juleber [^112juSiR]. U.S. Food and Drug Administration (2024). High credibility.

When taking JULEBERTM, the first orange "active" tablet should be taken on the first Sunday after menstruation begins. If menstruation starts on a Sunday, the first orange "active" tablet is also taken on that day. If switching directly from another oral contraceptive, the first orange "active" tablet should be taken on the first Sunday following the last active tablet of the previous product. Tablets are taken continuously as follows: one orange "active" tablet daily for 21 days, followed by one white "reminder" tablet daily for 7 days. After completing the 28 tablets, a new course begins the next day (Sunday), with the administration of an orange "active" tablet. When initiating a Sunday start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.

Use of JULEBERTM for contraception may be initiated 4 weeks postpartum. When administered during the postpartum period, the increased risk of thromboembolic disease associated with this time must be considered. If the patient starts on JULEBERTM postpartum and has not yet had a period, she should be advised to use another method of contraception until an orange "active" tablet is taken daily for 7 consecutive days. The possibility of ovulation and conception before starting the medication should be considered. If the patient misses one orange "active" tablet during Weeks 1, 2, or 3, the missed orange "active" tablet should be taken as soon as possible.

---

### Mental health gap action programme (mhGAP) guideline for mental, neurological and substance use disorders [Internet] [^117RCNZV]. Geneva: World Health Organization (2023). High credibility.

Regarding the medical management of bipolar disorder, specifically in terms of maintenance therapy, the WHO 2023 guidelines recommend considering mood stabilizers such as carbamazepine, lithium, or valproic acid. Alternatively, antipsychotics like aripiprazole, olanzapine, or quetiapine should be offered for at least six months in adult patients with bipolar disorder in remission. This should be done while carefully balancing effectiveness, side effects, and individual preferences.

---

### KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease [^115pDD5w]. Kidney International (2024). High credibility.

Regarding medical management for chronic kidney disease, particularly concerning drug dose adjustments, KDIGO 2024 guidelines recommend communicating a clear plan to the patient and healthcare providers about when to restart medication that is discontinued during an acute illness. Additionally, they emphasize the importance of ensuring that this plan is documented in the medical record.

---

### Challenges to our understanding of endometriosis pain [^113uW2qU]. Journal of Minimally Invasive Gynecology (2006). Low credibility.

Endometriosis remains a diagnostic and therapeutic challenge despite decades of clinical experience and research. The multiple treatment options for endometriosis described in this symposium clearly indicate how difficult it can be to diagnose and effectively treat endometriosis with our understanding of the disease.

- **Three major challenges**: At least three major challenges to our understanding can be identified:
	1. Endometriosis does not always cause pain.
	2. Other causes of pelvic pain often coexist in patients with endometriosis.
	3. Common medical and surgical treatments for endometriosis are relatively nonspecific.

Insights from the articles in this symposium can help clinicians reach a new level of understanding of endometriosis and perhaps lead to more effective methods for diagnosing and treating this perplexing condition.

---

### Mental health gap action programme (mhGAP) guideline for mental, neurological and substance use disorders [Internet] [^114quTJt]. Geneva: World Health Organization (2023). High credibility.

Regarding the medical management of bipolar disorder, specifically in the context of managing acute mania, the WHO 2023 guidelines recommend offering oral antipsychotics — such as aripiprazole, haloperidol, olanzapine, paliperidone, or quetiapine — or mood stabilizers — such as carbamazepine, lithium, or valproic acid — to adult patients with manic episodes. It is crucial to carefully balance effectiveness, side effects, and individual preference in treatment decisions.

---

### Zyprexa intramuscular [^1179o813]. U.S. Food and Drug Administration (2016). Low credibility.

- **Patient counseling information**: Patients should review the FDA-approved Medication Guide for oral formulations of ZYPREXA. They should be advised to alert their prescriber if any concerns arise while taking ZYPREXA, either alone or in combination with fluoxetine. If they feel their condition is not improving or have any concerns, they should contact their doctor. When ZYPREXA is used in combination with fluoxetine, patients should also consult the Patient Counseling Information section of the package insert for Symbyax.

- **Medication guide**: Healthcare professionals should inform patients, families, and caregivers about the potential benefits and risks of ZYPREXA and counsel them on its appropriate use. A Medication Guide for ZYPREXA is available, and prescribers should ensure it is read and understood by patients and their families. They should encourage discussions about the Medication Guide's contents and provide answers to any questions. When ZYPREXA is used in combination with fluoxetine, they should also refer to the Medication Guide for Symbyax.

- **Elderly patients with dementia-related psychosis**: Patients and caregivers should be informed that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.

---

### Xanax [^1147JQWp]. U.S. Food and Drug Administration (2023). High credibility.

- **Risks from concomitant use with opioids**: Concomitant use of benzodiazepines, including Xanax, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe Xanax concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of Xanax than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid is initiated in a patient already taking Xanax, prescribe a lower initial dose of the opioid and titrate based on clinical response. Advise both patients and caregivers about the risks of respiratory depression and sedation when Xanax is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined [see Drug Interactions (7.1)].

- **Abuse, misuse, and addiction**: The use of benzodiazepines, including Xanax, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often involve the use of other substances.

---

### The role of case management in HIV treatment adherence: HPTN 078 [^117Xsqtp]. AIDS and Behavior (2022). Low credibility.

Various strategies have been evaluated to address these individual, social, and structural barriers to adherence. Several studies have examined the effect of provider relationships on patients' medication adherence. In a study of 2765 PLWH on ART living in four major U.S. cities, respondents who indicated more frequent interactions with providers who provided positive support (informational, emotional) had higher scores on medication self-efficacy, leading to higher medication adherence. Cultivating positive patient-provider relationships is proposed as especially important to engage traditionally disenfranchised groups, including African American PLWH and substance-using groups. Some studies suggest delivering HIV care through a case manager approach, in which a trained social worker works with a patient to develop a personalized plan.

A systematic review of 239 studies that included motivational interviewing (MI) concluded that MI may be an effective strategy to assist medication adherence among PLWH who face mental health or substance use issues. A multi-tiered intervention (Heart to Heart) based on MI, peer-support groups, and patient navigation with 95 Black and Latino PLWH not engaged in ART treatment found significant improvements in viral suppression. Financial incentives have been offered to address structural issues. A systematic review of integrated interventions concluded that combined approaches produced some favorable outcomes. Despite evidence that interventions including personalized MI alone or in the context of multilevel interventions could promote improved outcomes, further research is needed.

---

### The place of implementation science in the translational medicine continuum [^115sxzPG]. Psychological Medicine (2011). Low credibility.

There is a growing consensus that the transfer of knowledge from biomedical discoveries into patient and public benefit should be accelerated. At the same time, there is a persistent lack of conceptual clarity about the precise nature of the phases of the translational continuum necessary to implement this. In this paper, we propose an integrated schema to understand the five sequential phases that link basic biomedical research with clinical science and implementation. We discuss the nature of three blocks along this translational pathway and outline key issues that need to be addressed in removing such barriers.

The five research phases described are:

- **Basic science discovery (Phase 0)**: This initial phase involves fundamental research aimed at understanding biological mechanisms.
- **Early human studies (Phase 1)**: These studies assess safety, dosage, and preliminary efficacy.
- **Early clinical trials (Phase 2)**: This phase involves more detailed evaluation of safety and efficacy in a larger patient group.
- **Late clinical trials (Phase 3)**: These trials confirm efficacy, monitor side effects, and compare with standard treatments.
- **Implementation (Phase 4)**: This phase includes adoption in principle, early implementation, and persistence of implementation.

This schema also sets out three points where communication blocks can occur. The application of 'implementation science' is in its early stages within mental health and psychiatric research. This paper aims to develop a consistent terminology to understand the discovery, development, dissemination, and implementation of new interventions. By better understanding the factors that promote or delay knowledge flow across these blocks, we can accelerate progression along translational medicine pathways and realize earlier patient benefit.

---

### Suicide risk management for the sequenced treatment alternatives to relieve depression study: Applied NIMH guidelines [^111sv2ZL]. Journal of Psychiatric Research (2004). Low credibility.

The NIMH guidelines for managing subjects who are suicidal during their participation in clinical trials include a full range of procedures to minimize suicidal risk, yet no reports at the time of writing have shown how researchers should best implement these guidelines. The architects of the sequenced treatment alternatives to relieve depression (STAR*D) study operationalized and implemented the NIMH guidelines by developing a comprehensive set of procedures to detect, monitor, and manage suicidal subjects during a large, complex, multisite clinical trial.

Because of the large size of the study (anticipated n = 4000), the wide geographic distribution, the large number of treating STAR*D clinicians, the broad array of subjects with psychiatric and medical comorbidities, the focus on treatment-resistant depression, and the complexity of multiple treatment steps and randomization points in STAR*D, the risk of suicide and safety monitoring of suicidal subjects presented a unique challenge. This paper describes methods derived from the NIMH guidelines used to manage suicidal risk in STAR*D, including the use of an interactive voice response system to alert clinicians, regional center directors, and safety officers.

---

### Bipolar disorder diagnosis: challenges and future directions [^1136uMYZ]. Lancet (2013). High credibility.

Bipolar disorder can be associated with a range of conditions and symptoms, including alcohol use disorder, agitation, migraine, psychomotor retardation, hallucinations, and hypothyroidism. Patients may experience pressured speech, opioid use disorder, mania, irritability, and panic disorder. Additional symptoms might include excessive daytime sleepiness, increased energy, insomnia, mood changes, difficulty concentrating, restlessness, and feelings of worthlessness.

Weight gain, inflated self-esteem, decreased energy, a lack of interest, delusions, PTSD, OCD, schizophrenia, loss of appetite, and racing thoughts are also possible. Suicidal ideation, inappropriate guilt, weight loss, depression, increased appetite, hopelessness, generalized anxiety disorder, tobacco use, and ADHD may further complicate the clinical picture.

---

### Using long-acting injectable antipsychotics to enhance the potential for recovery in schizophrenia [^113S7WXM]. The Journal of Clinical Psychiatry (2020). Low credibility.

The goals of schizophrenia treatment are to control symptoms, prevent relapse, and improve functioning and quality of life. For many patients, these goals are not being met. This report highlights information provided by experts on:

- **Reasons for, impact of, and means to reduce relapse** in patients with schizophrenia, patient-centered and patient-reported assessments, and the benefits and risks of medication options, including long-acting injectable (LAI) antipsychotics.
- **Psychosocial interventions** that may improve adherence and help prevent relapse in individuals living with schizophrenia.

Modifiable risk factors for poor outcomes in patients with schizophrenia include longer duration of untreated illness, comorbid substance abuse, early nonresponse to an antipsychotic, and the number of relapses related to nonadherence. Recommendations include:

1. Adopting a patient-centered approach that incorporates the use of patient-reported outcome measures.
2. Selecting medications based on a balanced risk-benefit assessment, including a focus on addressing symptoms for which the agents were superior to placebo and/or active controls.
3. Considering LAIs as an alternative to oral medications, as they offer benefits such as reliable drug delivery, uncovering nonadherence and pseudo-resistance, and reduced relapse risk and mortality.
4. Implementing psychosocial interventions that have been proven to be effective in improving adherence and overall outcomes.

---

### Common questions about buprenorphine treatment for opioid use disorder [^116BJxct]. American Family Physician (2025). High credibility.

Regarding medical management for opioid use disorder, specifically concerning general principles, the AAFP 2025 guidelines recommend not requiring behavior therapy as a condition for receiving medications for OUD.

---

### Clomipramine hydrochloride [^117QWZev]. U.S. Food and Drug Administration (2019). Low credibility.

Healthcare professionals should inform patients, their families, and caregivers about the benefits and risks associated with clomipramine hydrochloride treatment, emphasizing its appropriate use. A patient Medication Guide titled "Antidepressant Medicines, Depression and Other Serious Mental Illness, and Suicidal Thoughts or Actions" is available and should be reviewed. Patients and their families should be encouraged to read this guide and assisted in understanding its contents. Opportunities should be provided for discussion and clarification of any questions regarding the guide. The full text of the Medication Guide is available at the end of this document.

Patients should be made aware of the following issues and instructed to inform their prescriber if they occur while taking clomipramine hydrochloride:

- **Clinical worsening and suicide risk**: Patients, families, and caregivers should remain vigilant for signs of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, or any other unusual behavioral changes, including worsening depression and suicidal ideation. These symptoms are especially crucial to monitor early during antidepressant treatment and when dosage adjustments are made. Families and caregivers should observe these symptoms on a daily basis.

---

### The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary [^1131NKx4]. The Journal of Clinical Psychiatry (2003). Low credibility.

A growing number of atypical antipsychotics are available for clinicians to choose from in the treatment of psychotic disorders. However, several important questions concerning medication selection, dosing and dose equivalence, and the management of inadequate response, compliance problems, and relapse have not been adequately addressed by clinical trials. To aid clinical decision-making, a consensus survey of expert opinion on the pharmacologic treatment of psychotic disorders was undertaken to address questions not definitively answered in the research literature.

- **Method**: Based on a literature review, a written survey was developed with 60 questions and 994 options. Approximately half of the options were scored using a modified version of the RAND 9-point scale for rating the appropriateness of medical decisions. For the other options, the experts were asked to write in answers (e.g. average doses) or check a box to indicate their preferred answer. The survey was sent to 50 national experts on the pharmacologic treatment of psychotic disorders, 47 (94%) of whom completed it. In analyzing the responses to items rated on the 9-point scale, consensus on each option was defined as a non-random distribution of scores by chi-square "goodness-of-fit" test. We assigned a categorical rank (first line/preferred choice, second line/alternate choice, third line/usually inappropriate) to each option based on the 95% confidence interval around the mean rating. Guideline tables indicating preferred treatment strategies were then developed for key clinical situations.

---

### Risk of neuropsychiatric adverse events associated with varenicline: Systematic review and meta-analysis [^114hkxJ3]. BMJ (2015). Low credibility.

This meta-analysis of 39 randomized controlled trials, involving 5,817 patients prescribed varenicline 1 mg twice daily and 4,944 patients prescribed placebo, found no increased risk of suicide or attempted suicide, suicidal ideation, depression, or death in individuals treated with varenicline. Almost half of the trial participants were chronic heavy smokers, smoking an average of 20 cigarettes a day for 26 years. Five separate trials, comprising 1,281 participants randomized to varenicline and 1,143 to placebo, reported a suicide and/or suicide attempt. One trial reported suicide only, three reported attempted suicide only, and one reported both suicide and attempted suicide. Two suicides and two attempts occurred in the varenicline group of the trials (0.08%), and two attempts occurred in the placebo group (0.05%).

Use of the maximum dose of varenicline (1 mg twice daily) was associated with a 28% increased risk of fatigue, a 56% increased risk of insomnia, a 63% increased risk of sleep disorders, and more than twice the risk of abnormal dreams. There was evidence of a 25% reduction in the risk of anxiety. When using risk differences, for every 1,000 patients, there were an additional 10 cases of fatigue, 40 cases of insomnia, 20 cases of sleep disorders, and 60 cases of abnormal dreams in those prescribed varenicline compared with placebo. Conversely, there were 10 fewer episodes of anxiety per 1,000 participants in the varenicline group compared with the placebo group (risk difference −0.01, 95% confidence interval −0.02 to −0.0003).

---

### Stimulant and designer drug use: Primary care management [^113MFoy2]. American Family Physician (2018). High credibility.

Regarding nonpharmacologic interventions for stimulant use disorder, particularly psychotherapy, AAFP 2018 guidelines recommend considering offering psychosocial treatment. This approach aims to improve short-term adherence to treatment for cocaine and amphetamine (including 3,4-methylenedioxymethamphetamine) use disorders and enhance abstinence rates.

---

### Adaptive care planning: A paradigm shift [^114tWPgf]. Journal of the American Geriatrics Society (2024). High credibility.

The phases of Adaptive Care Planning involve several crucial steps. The first step requires the provider or team to ascertain the patient and family's perspective and understanding of the situation. By approaching with an open, inquiring, and nonjudgmental attitude, the provider can help address any negative emotions, misunderstandings, or other difficult feelings often present that may interfere with open communication. Once these emotions are recognized and addressed, future communications are more likely to be productive and collaborative. Many communication tools and curricula, such as VitalTalk/GeriTalk, Serious Illness Communication, the Four Habits, and SPIKES protocol, have been developed to assist clinicians in developing necessary skills for this step.

The second step is to provide medical information tailored to the patient's specific situation. This information should be presented in small, digestible pieces, with frequent pauses and checks for understanding or emotional responses from patients and their family members. This approach may necessitate resuming the first task of gauging the patient and family's perspective again. It is beneficial to examine medical facts side by side with the patient and/or family, creating a comprehensive understanding of the patient's situation or condition, rather than delivering the information as a lecture. An abundance of guidance exists for delivering prognostic information effectively.

---

### Exploring the usefulness of comprehensive care plans for children with medical complexity (CMC): a qualitative study [^1148tvoH]. BMC Pediatrics (2013). Low credibility.

The Medical Home model recommends that children with special health care needs (CSHCN) receive a medical care plan outlining the child's major medical issues and care needs to assist with care coordination. While care plans are a primary component of effective care coordination, the creation and maintenance of care plans are time, labor, and cost-intensive, and the desired content of the care plan has not been studied. The purpose of this qualitative study was to understand the usefulness and desired content of comprehensive care plans by exploring the perceptions of parents and health care providers (HCPs) of children with medical complexity (CMC).

- **Methods**: This qualitative study utilized in-depth semi-structured interviews and focus groups. HCPs (n = 15) and parents (n = 15) of CMC who had all used a comprehensive care plan were recruited from a tertiary pediatric academic health sciences center. Themes were identified through grounded theory analysis of interview and focus group data.

- **Results**: A multi-dimensional model of perceived care plan usefulness emerged. The model highlights three integral aspects of the care plan: care plan characteristics, activating factors, and perceived outcomes of using a care plan. Care plans were perceived as a useful tool that centralized and focused the care of the child. Care plans were reported to flatten the hierarchical relationship between HCPs and parents, resulting in enhanced reciprocal information exchange and strengthened relationships. Participants expressed that a standardized template that is family-centered and

---

### Venlafaxine hydrochloride [^117DXoSF]. U.S. Food and Drug Administration (2021). High credibility.

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Venlafaxine Hydrochloride Extended-Release Tablets and counsel them in its appropriate use. A patient Medication Guide about "Antidepressant Medicines, Depression and Other Serious Mental Illness, and Suicidal Thoughts or Actions" is available for Venlafaxine Hydrochloride Extended-Release Tablets. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and assist them in understanding its contents. Patients should have the opportunity to discuss the contents of the Medication Guide and obtain answers to any questions. The complete text of the Medication Guide is reprinted at the end of this document.

Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Venlafaxine Hydrochloride Extended-Release Tablets:

- **Emotional and behavioral changes**: Anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania.
- **Mental health concerns**: Other unusual changes in behavior, worsening of depression, suicidal ideation.

Patients, their families, and their caregivers should be encouraged to be alert to these symptoms, especially early during antidepressant treatment.

---

### Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: A multicentre observational retrospective study [^117Pgavo]. Therapeutic Advances in Gastroenterology (2023). Low credibility.

The entire cohort of 84 patients was included in the safety analysis. During the 72-week follow-up period, 10 adverse events were reported in nine patients (10.7%). Four of these adverse events led to treatment discontinuation: one was due to uveitis recurrence, one to infection, one to an infusion reaction, and one to adenocarcinoma of the ileum. The remaining six adverse events did not require treatment discontinuation and included headache, infection, arthralgia, dyspnea, cutaneous rash, and odynophagia.

Two patients died during follow-up. A 91-year-old female patient was treated with ustekinumab for 70 weeks and died of pneumonia secondary to COVID-19 infection. A 63-year-old female patient, who was treated for 24 weeks and had multiple cardiovascular risk factors, died of acute mesenteric ischemia.

Ten patients who started treatment with ustekinumab had a history of neoplasms (including two with colon cancer, two with breast cancer, two with melanomas, one with bladder cancer, one with prostate cancer, one with astrocytoma, and one with tongue cancer). No tumor recurrence was observed in any of these patients. Additionally, four patients who started treatment with ustekinumab had a history of congestive heart failure, and no adverse events were observed in these cases.

During the 72 weeks of follow-up, seven patients (8.2%) required surgery: three due to strictures, two for perianal disease, one for enterocutaneous fistula, and one for adenocarcinoma of the ileum.

---

### SPL drug information for quetiapine fumarate [^1175dksd]. U.S. Food and Drug Administration. High credibility.

Regarding the use of quetiapine fumarate PO (also known as Seroquel) in patients with CrCl ≥ 10 mL/min: use is acceptable, and no dose adjustment is required.

---

### Systemic challenges in bipolar disorder management: A patient-centered approach [^115FZNBB]. Bipolar Disorders (2017). Low credibility.

In the last decade, continuous improvement methodologies from manufacturing have begun to be adapted to health care systems to alleviate the demand on health care services relative to supply. Methodologies such as Lean, Six Sigma, and Theory of Constraints have, in many cases, dramatically improved both the quality and throughput of patient care by capitalizing on existing resources, reducing waste and variability, and locating rate‐limiting steps in operational performance. By redesigning systems, changing policies, and redeploying resources, it is possible to significantly increase capacity with limited cost increases. Although operational excellence methodologies are in their early stages of implementation in the health care system, more evidence on their utility should be generated in mental health services where the literature is sparse.

An important insight from patient discussions is that BD management needs a coordinated approach that accounts for multiple aspects of patient−provider interaction, including policy making, standards of care, treatment alternatives, patient education, psychosocial support, objective diagnostics, and individualized treatment. Psychiatric research should focus on matters of the greatest concern for patients and their caregivers, such as comparative efficacy and safety of existing BD medications and alternative treatments. Appropriate organizational decisions need to be made by providers to integrate the progress achieved in psychoeducation, psychosocial support, and collaborative care into clinical practice and to adopt effective principles.

---

### Surgical management of neuroproliferative-associated vestibulodynia: A tutorial on vestibulectomy with vaginal advancement flap [^112CHspg]. American Journal of Obstetrics and Gynecology (2019). Low credibility.

Provoked vestibulodynia is an often underdiagnosed and mismanaged medical condition that impacts the lives of many women. When symptoms are due to a dramatically increased density of pain fibers in the vestibular endoderm, the condition is referred to as neuroproliferative-associated vestibulodynia. Unfortunately, assessment of pain fiber density can only be performed after surgery during histologic examination.

First-line therapies for this condition often include topical or oral medications targeting hyperalgesia and allodynia at the vulvar vestibule. However, in the setting of refractory disease, surgical treatment should be considered. The surgical video highlights anatomical landmarks as well as key surgical steps when performing a vulvar vestibulectomy with a vaginal advancement flap for the treatment of neuroproliferative-associated vestibulodynia.

Surgeons should have a thorough understanding of pertinent vulvar anatomical landmarks before performing this procedure. The goal of vulvar vestibulectomy, as described in this video, is to excise the entirety of the vestibule containing the pathologic density of afferent pain fibers.

This tutorial serves to identify key anatomical landmarks including Hart's line as well as outline the meticulous dissection required for successful completion of this procedure. We describe our surgical instrumentation as well as provide insight into steps that can be taken to minimize postoperative morbidity.